Loading data for NVCT — first visit, this takes a few seconds.

Alert

Nuvectis Pharma Inc. (NVCT)

NasdaqCM: NVCT · Real-Time Price · USD

19.60

+0.06 (0.31%)

At close: Aug 13, 2026, 3:22 PM

0.31% (1D)

No data available

Bid	n/a
Market Cap	638.6M
Revenue (ttm)	n/a
Net Income (ttm)	-30.27M
Beta	-0.26
EPS (ttm)	-1.32
PE Ratio (ttm)	n/a
Forward PE	-20.42
P/B (ttm)	57.65
P/S (ttm)	n/a
Earnings Date	Nov 3, 2026

Ask	n/a
Volume	29,718
Avg. Volume (20D)	309,032
Open	19.88
Previous Close	19.54
Day's Range	19.36 - 20.01
52-Week Range	5.55 - 29.27
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About NVCT

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its na...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 4, 2022

Employees 16

Stock Exchange NasdaqCM

Ticker Symbol NVCT

Website https://www.nuvectis.com

Full Company Profile

Financial Performance

In 2025, Nuvectis Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.44M, an increase of 39.17%.

Financial Statements

Earnings Surprise

Nuvectis Pharma has released their quarterly earnings on Aug 4, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.3 misses estimates by -0.04, with 0.00% YoY growth.

Next Earnings Release

Nuvectis Pharma Inc. is scheduled to release its earnings on Nov 3, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

3 weeks ago · Zacks

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

1 month ago · Zacks

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...

1 month ago · Zacks

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?

Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · InvestorsHub

Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)

Secondary offering priced well below previous closeNuvectis Pharma (NASDAQ:NVCT) shares dropped 25% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company priced a $100 mil...

1 month ago · Zacks

What Makes Nuvectis Pharma (NVCT) a New Buy Stock

Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Page 1 of 2

Nuvectis Pharma Inc. (NVCT)